Loading ETF research
Fetching the latest fund profile, holdings, and market data.
Fetching the latest fund profile, holdings, and market data.
NASDAQ · Equity
$116.63
+$1.55 · +1.35%
· Aug 21, 4:00 PM ET
$116.63
Previous close+$1.55 · +1.35%
· Aug 21, 4:00 PM ET
$116.63
+$1.55 · +1.35%
Regular session · ET · Market data may be delayed.
VanEck Pharmaceutical ETF (PPH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Fund assets
1.07B USD
Expense ratio
0.36%
NAV
$116.61
Average volume
239.62K
Volume
143.23K
Day range
$114.72 – $117.43
52-week range
$85.91 – $117.73
Previous close
$115.08
Price change
1 day
+1.35%
1 month
+6.08%
3 months
+11.09%
Year to date
+13.05%
1 year
+32.68%
3 years
+41.66%
5 years
+51.41%
Price changes exclude distributions, fees, taxes, and investor-specific cash flows.
Portfolio
Holdings data updated Aug 23, 2026.
Portfolio composition
Fund income
Jul 1, 2026
Quarterly
Jul 1, 2026
Jul 7, 2026
$0.6248
Apr 1, 2026
Quarterly
Apr 1, 2026
Apr 7, 2026
$0.8441
Dec 29, 2025
Irregular
Dec 29, 2025
Dec 31, 2025
$0.3106
Oct 1, 2025
Quarterly
Oct 1, 2025
Oct 6, 2025
$0.3931
Jul 1, 2025
Quarterly
Jul 1, 2025
Jul 7, 2025
$0.6069
Apr 1, 2025
Quarterly
Apr 1, 2025
Apr 4, 2025
$0.5245
Dec 27, 2024
Irregular
Dec 27, 2024
Dec 30, 2024
$0.411
Oct 1, 2024
Quarterly
Oct 1, 2024
Oct 4, 2024
$0.409
Jul 1, 2024
Quarterly
Jul 1, 2024
Jul 5, 2024
$0.3558
Apr 1, 2024
Quarterly
Apr 2, 2024
Apr 5, 2024
$0.5328
Latest coverage
More funds
Continue in GoAI
Connect this ETF with broader market context and continue your research in GoAI.
ETF data may be delayed, incomplete, or revised. Holdings and exposures change over time. Historical performance does not guarantee future results. This page is for informational and educational purposes only and does not constitute investment advice or a recommendation.
